Compare Stocks: PLX, CADL, RIGL, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$15.72 +2.7%	$18.56	$10.70 ▼ $24.27	$885.43M	0.78	985,279 shs	1.90 million shs
CADL Candel Therapeutics	$11.55 +2.3%	$11.42	$4.35 ▼ $14.00	$906.74M	-0.48	1.17 million shs	880,454 shs
PLX Protalix BioTherapeutics	$2.75 -1.8%	$2.51	$1.60 ▼ $3.19	$221.57M	0.02	911,394 shs	302,265 shs
RIGL Rigel Pharmaceuticals	$47.89 -0.5%	$43.56	$24.95 ▼ $52.24	$903.27M	1.2	235,312 shs	143,804 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.75%	-5.81%	-20.36%	-13.45%	+35.52%
CADL Candel Therapeutics	+2.30%	+1.85%	-15.07%	+17.98%	+112.71%
PLX Protalix BioTherapeutics	-1.79%	+1.85%	+14.58%	+19.57%	+33.50%
RIGL Rigel Pharmaceuticals	-0.50%	+4.45%	+2.44%	+23.78%	+58.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$15.72 +2.7%	$18.56	$10.70 ▼ $24.27	$885.43M	0.78	985,279 shs	1.90 million shs
CADL Candel Therapeutics	$11.55 +2.3%	$11.42	$4.35 ▼ $14.00	$906.74M	-0.48	1.17 million shs	880,454 shs
PLX Protalix BioTherapeutics	$2.75 -1.8%	$2.51	$1.60 ▼ $3.19	$221.57M	0.02	911,394 shs	302,265 shs
RIGL Rigel Pharmaceuticals	$47.89 -0.5%	$43.56	$24.95 ▼ $52.24	$903.27M	1.2	235,312 shs	143,804 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.75%	-5.81%	-20.36%	-13.45%	+35.52%
CADL Candel Therapeutics	+2.30%	+1.85%	-15.07%	+17.98%	+112.71%
PLX Protalix BioTherapeutics	-1.79%	+1.85%	+14.58%	+19.57%	+33.50%
RIGL Rigel Pharmaceuticals	-0.50%	+4.45%	+2.44%	+23.78%	+58.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	186.90% Upside
CADL Candel Therapeutics	2.73	Moderate Buy	$20.14	74.40% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	336.36% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	23.20% Upside

Current Analyst Ratings Breakdown

Latest PLX, CADL, RIGL, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	PLX Protalix BioTherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	14,051.06	N/A	N/A	$4.49 per share	3.50
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
PLX Protalix BioTherapeutics	$80.62M	2.75	$0.15 per share	17.80	$0.47 per share	5.85
RIGL Rigel Pharmaceuticals	$294.28M	3.01	$6.61 per share	7.24	$21.57 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.23	N/A	8.87	N/A	-21.03%	-30.89%	-11.74%	N/A
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.93	11.09	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest PLX, CADL, RIGL, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
CADL Candel Therapeutics	0.38	16.09	16.09
PLX Protalix BioTherapeutics	N/A	1.98	1.27
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CADL Candel Therapeutics	13.93%
PLX Protalix BioTherapeutics	16.53%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
CADL Candel Therapeutics	14.30%
PLX Protalix BioTherapeutics	6.70%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
PLX Protalix BioTherapeutics	226	80.57 million	69.00 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

PLX, CADL, RIGL, and AVTX Headlines

Recent News About These Companies

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up - Here's What Happened

September 23 at 11:39 AM | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 20, 2026 | americanbankingnews.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages

September 20, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 15, 2026 | seekingalpha.com

Rigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreed

September 15, 2026 | nl.investing.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 15, 2026 | seekingalpha.com

Squarepoint Ops LLC Acquires 38,550 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 14, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL

September 6, 2026 | marketbeat.com

Man Group plc Invests $814,000 in Rigel Pharmaceuticals, Inc. $RIGL

September 4, 2026 | marketbeat.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL

August 27, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages

August 26, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, CADL, RIGL, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$15.72 +0.42 (+2.75%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$15.19 -0.53 (-3.37%)

As of 09/24/2026 07:35 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Candel Therapeutics NASDAQ:CADL

$11.55 +0.26 (+2.30%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$11.45 -0.10 (-0.85%)

As of 09/24/2026 07:41 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$2.75 -0.05 (-1.79%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.79 +0.04 (+1.60%)

As of 09/24/2026 07:59 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Rigel Pharmaceuticals NASDAQ:RIGL

$47.89 -0.24 (-0.50%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$47.59 -0.30 (-0.62%)

As of 09/24/2026 07:56 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, CADL, RIGL, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, CADL, RIGL, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, CADL, RIGL, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, CADL, RIGL, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Candel Therapeutics NASDAQ:CADL

Protalix BioTherapeutics NYSE:PLX

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, CADL, RIGL, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, CADL, RIGL, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, CADL, RIGL, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, CADL, RIGL, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Candel Therapeutics NASDAQ:CADL

Protalix BioTherapeutics NYSE:PLX

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools